FOI-01829

#Request# Can you provide data on English and/or UK spend (in £GBP) on the following branded medicines for the last full year for which data is available (stating year): Revolade (eltrombopag),Cerdelga (eliglustat), Vyndaqel (tafamidis), Opsumit (macitentan), Ocaliva (obeticholic acid), Uptravi (selexipag), Esbriet (pirfenidone), Kalydeco (ivacaftor), Adempas (riociguat) #Response# Under Section 21 of the Act, we are not required to provide information in response to a request if it is already reasonably accessible to you. The net ingredient cost (NIC) is available at chemical substance and product level from the following web links. The files can be filtered by product name to locate the information you require: Prescription cost analysis (PCA) for the calendar year 2023: https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-annual-statistics PCA for the latest 12 months Jan 23 - Jan 24. For this you will need to extract each month separately https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-monthly-data The English prescribing dataset (EPD) contains information on prescriptions issued in England that have been dispensed in England, Wales, Scotland, Guernsey, Alderney, Jersey, and the Isle of Man. https://opendata.nhsbsa.net/dataset/english-prescribing-data-epd